Post-Acute COVID Biomarker Patterns Vary by Symptom and Time
METHODOLOGY:
PASC affects a considerable number of people after mild acute SARS-CoV-2 infection, but data on its pathophysiologic mechanisms remain limited. In this study, researchers explored symptoms associated with PASC and examined its association with a range of blood biomarkers.
They included participants with prior SARS-CoV-2 infection either asymptomatic or without persistent symptoms categorized into recovered (n = 490) and PASC (n = 311) groups, using data from three French population-based cohorts collected between February 2020 and October 2021.
Participants received two home visits at baseline and 6 months for biological sample collection and completed questionnaires covering medical history, infection status, vaccination status, symptoms, and mental health.
Researchers assessed 14 blood biomarkers, including cytokines, chemokines, immune checkpoints, cell adhesion molecules, and markers of macrophage activation and vascular damage, which are known to be involved in the pathophysiologic mechanisms of SARS-CoV-2 infection.
TAKEAWAY:
Participants with PASC commonly reported persistent fatigue, breathlessness, cough, and sleep disorders, along with higher rates of depression and anxiety.
Inflammatory biomarkers linked to COVID-19 severity (IFN gamma and CD163) and vascular activation markers (VCAM-1 and ICAM-1) showed significant correlations with specific PASC symptoms, particularly among participants infected within the past year; however, these associations largely disappeared over time.
Viral activation markers (PD-L1 and IP-10) were positively associated with acute-phase symptoms such as anosmia/ageusia and cough, particularly in recent infections.
Complete symptom resolution was more common among participants with recent infections (< 1 year ago) than among those infected a year ago, occurring in 38% vs 20% of cases ( P = .04). Overall, 74% of individuals experienced a resolution of at least one symptom.
IN PRACTICE:
'Biomarker profiles appear to vary according to symptom type and the time elapsed since infection. Consequently, research efforts and treatment strategies should take these parameters into account,' the authors wrote.
SOURCE:
This study was led by Olivier Robineau, Sorbonne Université, Inserm, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Paris, France. It was published online on May 30, 2025, in eBioMedicine .
LIMITATIONS:
Individuals with more severe symptoms may have been particularly motivated to participate, introducing selection bias. Additionally, as most biomarker measurements were taken long after participants' initial infection and only a few participants had recent infections, the ability to identify associations specific to the acute phase was likely diminished.
DISCLOSURES:
This study received funding from the French Ministry of Health and Prevention and the French Ministry of Higher Education, Research and Innovation. Two authors disclosed receiving financial support from Gilead, ViiV, MSD, Moderna, or Pfizer or nonfinancial support from Nordic Pharma France.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Salton Sea not to blame for Coachella, Imperial air pollution, study says
For years, millions of dollars have poured into controlling dust that wafts off the exposed lake shoreline of the Salton Sea, hoping to solve a serious air pollution problem in the Coachella and Imperial valleys. But a new report finds that the dusty shoreline is only responsible for a small percentage of the pollution, prompting some researchers to emphasize that cleaner air inside people's homes, workplaces and schools could be more important in addressing the asthma and respiratory disease that plague the area. "My big takeaway is that there's so many different sources that what we really need to do is pivot away from source control to start protecting people where they're exposed,' said Michael Cohen, a senior researcher at the Pacific Institute and lead author of the report. Released Thursday, the report draws on data from local, state and federal agencies and finds that dust from the expanding dry shore of the Salton Sea accounts for less than 1% of total small particle pollution in the region. The Salton Sea Basin, Coachella Valley and Imperial Valley all violate ozone, or smog, limits. When averaged over the year, Imperial Valley and Salton Sea Basin have twice the state limit for larger particles. Recent research also suggests bacteria and hydrogen sulfide as pollutants of concern. The dust particles are made up of agricultural chemicals from miles of lettuce and spinach fields, manure from livestock operations, diesel exhaust, unpaved roads and fine debris from lithium mining. Previous reports from UC Riverside have called the area one of the most impoverished and environmentally deteriorated regions in California. This mix is why state and local agencies have long focused their attention on dust control projects, planting salt-tolerant vegetation and spreading gravel. To date, California has spent some $49 million to put in more than 3,000 acres of dust suppression around the Salton Sea. But pollution is coming from so many places that money may be best spent in other ways, the researchers say. 'It's just much more effective, more cost-effective to switch to exposure control ... because really, at the end of the day, we're trying to protect public health and improve the lives of people," Cohen said. That could mean focusing on distributing filters, weatherizing homes and alerting people when they should stay and avoid exercising outdoors. A 2023 survey by the UCR School of Medicine showed more than one in five children in communities near the Salton Sea have asthma — almost twice the state average. Some 29% of parents surveyed said their child has had wheezing or breath whistling in the past, most in the last 12 months. The Salton Sea's role in the region's air quality is amplified by its geography. As a desert basin bordered by mountains, it can trap pollutants. Since 2018, the Salton Sea no longer gets an inflow of fresh water, only agricultural runoff, so it is evaporating and shrinking while the exposed, dry lake bed area is expanding, feeding clouds of particulate. Wind patterns, including strong gusts that sweep across the lake bed and surrounding farmland, can also kick up fine, toxic particles and carry them into nearby towns — exposing more residents. Some of the communities have identified pesticides, open burning, road dust and farming operations as among their air priorities. The region includes Calipatria, Brawley, Riverside, Palm Desert and Indio as well smaller communities, many of them mostly Latino or Indigenous. It's not that the Salton Sea is ruled out as a health problem. Dr. David Lo, a UC Riverside professor who has focused for years on air pollution in the region, said certain particles can be especially harmful depending on their chemical or biological makeup. 'A tiny amount of toxic material, even if it's infinitesimally small, can still have really major health effects,' Lo said. If policy emphasis were to shift to indoor air quality, that would leave many people unprotected, said Aydee Rodriguez, environmental justice campaign manager for the nonprofit Alianza Coachella Valley. "We've been noticing an uptick … of asthma-related … emergencies, people having nosebleeds, people having migraines, people feeling dizzy, nauseous,' she said. 'My hope is that the people start to get together and start talking to each other," said study author Cohen. "About what the different agencies are doing, where they're investing their money and how they can leverage and optimize those investments in public health.' This story originally appeared in Los Angeles Times.
Yahoo
an hour ago
- Yahoo
Faro, Yukon without primary care paramedic this weekend
There will be no primary care paramedic or nurses in Faro, Yukon, this weekend. In a post on its Facebook page, the Town of Faro said there will be no primary care paramedic in the community from Aug. 15 to Aug 19. The news comes during a temporary closure of the town's health centre because there are no nurses to staff it. The closure began Aug. 6 and is expected to last until Sept. 5. "Community members should call 911 for any emergencies and EMS [emergency medical service] dispatch will coordinate resources as needed," the post said. During the health centre closure, a primary care paramedic was meant to provide emergency coverage. Now, local volunteers might be the first to respond to emergencies over the weekend. "There will be two volunteer emergency medical responders on call, except [from] between August 18 at 8 p.m. [to] August 19 at 2 p.m.," said Nigel Allan with Yukon Health and Social Services. Allan says EMS will continue to respond to 911 calls in Faro and will dispatch the appropriate responders. "So if that's an EMS team from a neighbouring community or deploy fixed-wing [plane] or helicopter transport from Whitehorse, they'll make that determination as they normally would in any situation for a community." 'We're in the wilderness without health care' Douglas Tutty, a retired nurse and a volunteer firefighter who has lived in Faro since 2018, said primary care paramedics are responsible for assessing patients and determining if they require a medevac. Now, without a primary car paramedic, he said those assessments can't be made in the community. He said EMS will have take someone elsewhere to assess whether they need a medevac, and the closest community where that can happen is in Ross River, an hour and 15 minutes away. Tutty is concerned about the town's capacity to respond to a medical emergency this weekend. "We're in the wilderness and without health care." CBC News has reached out to the mayor of Faro for comment. As of publishing time, he had not done an interview.
Yahoo
an hour ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
